Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial

Johan A. Maertens, Issam I. Raad, Kieren A. Marr, Thomas F. Patterson, Dimitrios P. Kontoyiannis, Oliver A. Cornely, Eric J. Bow, Galia Rahav, Dionysios Neofytos, Mickael Aoun, John W. Baddley, Michael Giladi, Werner J. Heinz, Raoul Herbrecht, William Hope, Meinolf Karthaus, Dong Gun Lee, Olivier Lortholary, Vicki A. Morrison, Ilana OrenDominik Selleslag, Shmuel Shoham, George R. Thompson, Misun Lee, Rochelle M. Maher, Anne Hortense Schmitt-Hoffmann, Bernhardt Zeiher, Andrew J. Ullmann

Producción científica: Articlerevisión exhaustiva

682 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial'. En conjunto forman una huella única.

Pharmacology, Toxicology and Pharmaceutical Science